Viability of covering clinical blood cost in medical insurance
10.13303/j.cjbt.issn.1004-549x.2021.02.028
- VernacularTitle:临床用血费用纳入医疗保障范围的可行性分析
- Author:
Xiaoqian HUANG
1
;
Yao TANG
1
;
Bin LIU
1
;
Aimin LIU
1
;
Zhong LIU
1
Author Information
1. Blood Safety Administration Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Science, Chengdu 610052, China
- Publication Type:Journal Article
- Keywords:
blood cost;
medical insurance;
viability
- From:
Chinese Journal of Blood Transfusion
2021;34(2):193-196
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To analyze the viability of covering blood cost in medical insurance in China and discuss the necessity and practicability, so as to provide references for the improvement of medical insurance mechanism. 【Methods】 A questionnaire was designed and issued to blood centers covering 31 provinces /municipalities/autonomous regions in June 2019, and respective information regarding basic medical diagnosis and treatment directory, as well as normative documents on the official websites was collected and analyzed. 【Results】 13 out of 31 provinces /municipalities/autonomous regions had introduced the relevant policies of covering blood cost in medical insurance. Concerning the other 18 respondents, a total of 52 cities in 9 provinces had issued relevant policies. 5.01 billion RMB was included in medical insurance in 2017, accounting for 61.00% of the total clinical blood cost. 【Conclusion】 Less economic burden and less impact on voluntary blood donation recruitment could be realized by setting clinical blood price by the government.
